The emerging roles of γδ T cells in cancer immunotherapy
S Mensurado, R Blanco-Domínguez… - Nature Reviews Clinical …, 2023 - nature.com
Current cancer immunotherapies are primarily predicated on αβ T cells, with a stringent
dependence on MHC-mediated presentation of tumour-enriched peptides or unique …
dependence on MHC-mediated presentation of tumour-enriched peptides or unique …
Gamma delta T-cell based cancer immunotherapy: past-present-future
J Saura-Esteller, M De Jong, LA King… - Frontiers in …, 2022 - frontiersin.org
γδ T-cells directly recognize and kill transformed cells independently of HLA-antigen
presentation, which makes them a highly promising effector cell compartment for cancer …
presentation, which makes them a highly promising effector cell compartment for cancer …
Cancer immunotherapy with γδ T cells: many paths ahead of us
D Kabelitz, R Serrano, L Kouakanou, C Peters… - Cellular & molecular …, 2020 - nature.com
Abstract γδ T cells play uniquely important roles in stress surveillance and immunity for
infections and carcinogenesis. Human γδ T cells recognize and kill transformed cells …
infections and carcinogenesis. Human γδ T cells recognize and kill transformed cells …
γδ T cells: origin and fate, subsets, diseases and immunotherapy
Y Hu, Q Hu, Y Li, L Lu, Z **ang, Z Yin… - … and Targeted Therapy, 2023 - nature.com
The intricacy of diseases, shaped by intrinsic processes like immune system exhaustion and
hyperactivation, highlights the potential of immune renormalization as a promising strategy …
hyperactivation, highlights the potential of immune renormalization as a promising strategy …
Exploiting innate immunity for cancer immunotherapy
M Yi, T Li, M Niu, Q Mei, B Zhao, Q Chu, Z Dai, K Wu - Molecular cancer, 2023 - Springer
Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …
However, most of these immunomodulatory strategies focus on harnessing adaptive …
γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer
The potential of cancer immunotherapy relies on the mobilization of immune cells capable of
producing antitumour cytokines and effectively killing tumour cells. These are major …
producing antitumour cytokines and effectively killing tumour cells. These are major …
Selection of cross-reactive T cells by commensal and food-derived yeasts drives cytotoxic TH1 cell responses in Crohn's disease
GR Martini, E Tikhonova, E Rosati, MB DeCelie… - Nature medicine, 2023 - nature.com
Aberrant CD4+ T cell reactivity against intestinal microorganisms is considered to drive
mucosal inflammation in inflammatory bowel diseases. The disease-relevant microbial …
mucosal inflammation in inflammatory bowel diseases. The disease-relevant microbial …
The present and future of bispecific antibodies for cancer therapy
Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …
applications that cannot be achieved using conventional IgG-based antibodies …
Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
SK Daniel, KM Sullivan, KP Labadie… - Clinical and translational …, 2019 - Springer
Pancreatic ductal adenocarcinoma (PDA) is a lethal disease with limited response to
cytotoxic chemoradiotherapy, as well as newer immunotherapies. The PDA tumor …
cytotoxic chemoradiotherapy, as well as newer immunotherapies. The PDA tumor …
Bispecific immunomodulatory antibodies for cancer immunotherapy
B Blanco, C Domínguez-Alonso… - Clinical Cancer Research, 2021 - AACR
The recent advances in the field of immuno-oncology have dramatically changed the
therapeutic strategy against advanced malignancies. Bispecific antibody-based …
therapeutic strategy against advanced malignancies. Bispecific antibody-based …